OmniAb (OABI) Capital Expenditures (2022 - 2026)
OmniAb (OABI) posted quarterly Capital Expenditures of $167000.0 for Q1 2026, down 20.1% year-over-year from $209000.0 in Q1 2025, and down 84.49% quarter-over-quarter from $1.1 million in Q4 2025.
OmniAb (OABI) Capital Expenditures (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported Capital Expenditures for 5 consecutive years, with $167000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 20.1% year-over-year to $167000.0; the TTM figure through Mar 2026 stood at $523000.0 (down 67.72% YoY), while the FY2025 annual figure was $565000.0, down 69.87% from the prior year.
- Capital Expenditures retreated to $167000.0 in Q1 2026 per OABI's latest filing, from $1.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.5 million in Q4 2022 and bottomed at -$5.4 million in Q3 2022.
- Historically, Capital Expenditures has averaged $238941.2 across 5 years, with a median of $317000.0 in 2023.
- On a YoY basis, Capital Expenditures climbed as much as 537.74% in 2024 and fell as far as 2810.39% in 2024.
- OmniAb's Capital Expenditures stood at $2.5 million in 2022, then tumbled by 79.04% to $533000.0 in 2023, then jumped by 357.6% to $2.4 million in 2024, then sank by 55.84% to $1.1 million in 2025, then tumbled by 84.49% to $167000.0 in 2026.
- Business Quant data shows OABI's Capital Expenditures at $167000.0 in Q1 2026, $1.1 million in Q4 2025, and -$886000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 110,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110,000.00 |
| Jun 30, 2026 | 110,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Dec 31, 2025 | 1.08 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | -886,000.00 |
| Sep 30, 2025 | -886,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 464,000.00 |
| Mar 31, 2024 | 464,000.00 |